By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Rosetta Genomics today said that it has signed definitive agreements to sell 8.1 million shares of its stock to certain investors at $0.17 apiece, which would raise $1.4 million for the beleaguered microRNA diagnostics firm.

Rosetta said that the transactions are expected to close on April 17. The proceeds of the offering will be used to fund operations and other general corporate purposes, including the repayment of debt.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Mary Beckerle has been removed as director of the Huntsman Cancer Institute in what one researcher refers to as a "coup," ScienceInsider reports.

Bill Gates tells the Telegraph that bioterrorism is a serious risk.

The March for Science is to take place tomorrow, and supporters are tapping their creative energies to create placards to carry.

CBS News reports that the White House Science Fair is to continue under President Donald Trump.